top
Search terms
Results 1 - 10 of 214 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 22
Ehjournal

Abstract Aims ILUMIEN I is the largest prospective, non-randomized, observational study of percutaneous coronary intervention (PCI) procedural practice in patients undergoing intra-procedural pre- ...

European Heart Journal, FASTTRACK TO EuroPCR, William Wijns, Junya Shite, Michael R. Jones, Stephen W.-L. Lee, Matthew J. Price, Franco Fabbiocchi, Emanuele Barbato, Takashi Akasaka, Hiram Bezerra, ...

Date : 14/12/2015 Item size : 300220 bytes
Ehjournal

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting Methods Study design ISAR-SAFE is an investigator-initiated, ...

European Heart Journal, Thrombosis and antithrombotic therapy, Stefanie Schulz-Schüpke, Robert A. Byrne, Jurrien M. ten Berg, Franz-Josef Neumann, Yaling Han, Tom Adriaenssens, Ralph Tölg, ...

Date : 21/05/2015 Item size : 364593 bytes
Ehjournal

The purpose of this randomized trial was to compare the arterial healing response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting stent ...

European Heart Journal, FASTTRACK CLINICAL RESEARCH, Manel Sabaté, Stephan Windecker, Andres Iñiguez, Lisette Okkels-Jensen, Angel Cequier, Salvatore Brugaletta, Sjoerd H. Hofma, Lorenz ...

Date : 14/01/2016 Item size : 415299 bytes
Ehjournal

The primary endpoint, a composite of death, myocardial infarction, ischaemia-driven revascularization, or stent thrombosis, and the primary safety endpoint, Global Use of Strategies to Open Occluded ...

European Heart Journal, FASTTRACK ESC Clinical Trial Update, J. Antonio Gutierrez, Robert A. Harrington, James C. Blankenship, Gregg W. Stone, Ph. Gabriel Steg, C. Michael Gibson, Christian W. Hamm, ...

Date : 07/04/2016 Item size : 269898 bytes
Ehjournal

Table 1Baseline clinical characteristics VariablesN = 1012 Patient age, years 62.3 ± 11.1 Male sexa 781 (77.2%) Diabetes mellitusa 201 (19.9%) Hypertensiona 622 (61.5%) Hyperlipidaemiaa 597 ...

European Heart Journal, Fasttrack Clinical, Kyohei Yamaji, Lorenz Räber, Thomas Zanchin, Ernest Spitzer, Christian Zanchin, Thomas Pilgrim, Stefan Stortecky, Aris Moschovitis, Michael Billinger, ...

Date : 01/12/2016 Item size : 329548 bytes
Ehjournal

After Andreas Grüntzigs seminal first coronary angioplasty with a self-designed balloon nearly 40 years ago in Zurich,1 it became obvious that dissections and restenosis formation severely ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/12/2016 Item size : 197777 bytes
Ehjournal

Eighteen months before, he received bioresorbable vascular scaffolds (BVS) in the left anterior descending coronary artery (LAD) and obtuse marginal (OM) branch in Kuwait. After thrombosuction ...

European Heart Journal, CARDIOVASCULAR FLASHLIGHT, Leo Timmers, Pieter R. Stella, Pierfrancesco Agostoni

Date : 07/02/2015 Item size : 122358 bytes
Ehjournal

To maximize the effectiveness of therapy and reduce the hazard of bleeding, ischaemic and bleeding risks should be evaluated on an individual basis. 18.1 Percutaneous coronary intervention in stable ...

European Heart Journal, ESC/EACTS Guidelines, Authors/Task Force members, Stephan Windecker, Philippe Kolh, Fernando Alfonso, Jean-Philippe Collet, Jochen Cremer, Volkmar Falk, Gerasimos Filippatos, ...

Date : 01/10/2014
Ehjournal

Clopidogrel replaced ticlopidine as a safer thienopyridine for P2Y12 inhibition, but does not have universal efficacy due to poor efficiency of active metabolite formation in some individuals, only ...

European Heart Journal, Editorial, Robert F. Storey

Date : 14/07/2015
Ehjournal

Non-specific protein and cellular binding of UFH results in variable biological activity and can result in heparin-induced thrombocytopenia and thrombosis. [...]UFH binds to the glycoprotein ...

European Heart Journal, Editorial, Gregg W. Stone

Date : 07/09/2014